GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC

GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC
Adding Celsion's GEN-1 to standard chemotherapy — given prior to surgery — stops disease progression in patients with newly diagnosed advanced ovarian cancer and helps remove the tumor successfully during surgery, without causing significant side effects, a Phase 1b trial shows. The trial's data were presented at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium, held in San Francisco from Feb. 28 to March 2. The oral presentation was titled "Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer." GEN-1 is a DNA-based immunotherapy that induces a sustained production and release of a pro-inflammatory molecule called interleukin-12 (IL-12), triggering an immune response against malignant cancer cells. The recently completed OVATION I study (NCT02480374) was designed to assess the safety and effectiveness of eight weekly treatments of GEN-1 (injected into the abdominal cavity) combined with chemotherapy in patients with newly diagnosed advanced ovarian cancer who underwent surgery after chemo. The study included four dose groups (36 mg/m2, 47 mg/m2, 61 mg/m2 and 79 mg/m2), designed to include three to six patients per group, to find the dose with the
Subscribe or to access all post and page content.

Tagged , , , , .

Joana holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. She is currently finishing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

Leave a Comment

Your email address will not be published. Required fields are marked *